Patents by Inventor Mirco Meniconi
Mirco Meniconi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897866Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: GrantFiled: November 9, 2021Date of Patent: February 13, 2024Assignee: Padlock Therapeutics, Inc.Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
-
Publication number: 20230287003Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: October 18, 2022Publication date: September 14, 2023Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
-
Patent number: 11512095Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: GrantFiled: April 12, 2019Date of Patent: November 29, 2022Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
-
Publication number: 20220242846Abstract: Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, —C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —CHO, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, —O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, —O-(4-8 membered heterocycloalkyl), —O—C1-4 alkyl-(4-8 membered heterocycloalkyl), —OC(O)—C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substiType: ApplicationFiled: April 8, 2022Publication date: August 4, 2022Inventors: Alexander Flohr, Oliv Eidam, Bernhard Fasching, Mirco Meniconi, Amine Sadok, Rajesh Chopra, Hannah Zhu` Ai Wang, John Jamieson Caldwell, Ian Collins, Thomas Ryckmans
-
Publication number: 20220081418Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: ApplicationFiled: November 9, 2021Publication date: March 17, 2022Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
-
Patent number: 11198681Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: GrantFiled: February 22, 2017Date of Patent: December 14, 2021Assignee: Padlock Therapeutics, Inc.Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
-
Publication number: 20210299115Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: ApplicationFiled: May 12, 2021Publication date: September 30, 2021Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
-
Publication number: 20210188810Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: ApplicationFiled: February 22, 2017Publication date: June 24, 2021Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye
-
Patent number: 11026937Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: GrantFiled: September 11, 2017Date of Patent: June 8, 2021Assignee: Padlock Therapeutics, Inc.Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
-
Publication number: 20210163497Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: April 12, 2019Publication date: June 3, 2021Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
-
Patent number: 10703741Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: GrantFiled: July 27, 2017Date of Patent: July 7, 2020Assignee: Padlock Therapeutics, Inc.Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristina Lecci, Heather Tye
-
Publication number: 20190358216Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: ApplicationFiled: September 11, 2017Publication date: November 28, 2019Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
-
Publication number: 20190276432Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: ApplicationFiled: July 27, 2017Publication date: September 12, 2019Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristine Lecci, Heather Tye
-
Patent number: 9963448Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: GrantFiled: December 9, 2016Date of Patent: May 8, 2018Assignee: Padlock Therapeutics, Inc.Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
-
Patent number: 9963462Abstract: Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.Type: GrantFiled: September 30, 2016Date of Patent: May 8, 2018Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Mark Joseph Tebbe, Holly Victoria Atton, Craig Avery, Steven Mark Bromidge, Mark Kerry, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall
-
Publication number: 20170166565Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: ApplicationFiled: December 9, 2016Publication date: June 15, 2017Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
-
Publication number: 20170096435Abstract: Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.Type: ApplicationFiled: September 30, 2016Publication date: April 6, 2017Inventors: Mark Joseph Tebbe, Holly Victoria Atton, Craig Avery, Steven Mark Bromidge, Mark Kerry, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall
-
Publication number: 20100197699Abstract: The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is an aryl or heteroaryl; which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; W is —CZ1 or nitrogen; Z1 is hydrogen, C1-C4 alkyl; A is a 5 membered heteroaryl, pyrazine, pyrimidine, or quinoline or quinazoline which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; B is hydrogen or a 5-10 membered aryl or heteroaryl which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; being A and B linked via any atom; provided that when W is —CZ1, compounds of formula (I) have a trans stereochemistry; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the tType: ApplicationFiled: January 30, 2008Publication date: August 5, 2010Inventors: Jonathan Bentley, Matteo Biagetti, Francesca Cardullo, Thorsten Genski, Silvia Rosalia Kopf, Colin Philip Leslie, Sergio Melotto, Mirco Meniconi, Giancarlo Merlo, Domenica Antonia Pizzi, Catia Seri
